These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38042510)

  • 1. Enzymatic degradation pattern of polysorbate 20 impacts interfacial properties of monoclonal antibody formulations.
    Gregoritza K; Theodorou C; Heitz M; Graf T; Germershaus O; Gregoritza M
    Eur J Pharm Biopharm; 2024 Jan; 194():74-84. PubMed ID: 38042510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving Prediction of Free Fatty Acid Particle Formation in Biopharmaceutical Drug Products: Incorporating Ester Distribution during Polysorbate 20 Degradation.
    Doshi N; Martin J; Tomlinson A
    Mol Pharm; 2020 Nov; 17(11):4354-4363. PubMed ID: 32941040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of Polysorbate Ester Fractions and Implications in Protein Drug Product Stability.
    Tomlinson A; Zarraga IE; Demeule B
    Mol Pharm; 2020 Jul; 17(7):2345-2353. PubMed ID: 32442382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Degradation of Polysorbate 20 by Sialate O-Acetylesterase in Monoclonal Antibody Formulations.
    Zhang S; Xiao H; Li N
    J Pharm Sci; 2021 Dec; 110(12):3866-3873. PubMed ID: 34487744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating a Modified High Purity Polysorbate 20 Designed to Reduce the Risk of Free Fatty Acid Particle Formation.
    Doshi N; Ritchie K; Shobha T; Giddings J; Gregoritza K; Taing R; Rumbelow S; Chu J; Tomlinson A; Kannan A; Saggu M; Cai SK; Nicoulin V; Liu W; Russell S; Luis L; Yadav S
    Pharm Res; 2021 Sep; 38(9):1563-1583. PubMed ID: 34495486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Comprehensive Assessment of All-Oleate Polysorbate 80: Free Fatty Acid Particle Formation, Interfacial Protection and Oxidative Degradation.
    Doshi N; Giddings J; Luis L; Wu A; Ritchie K; Liu W; Chan W; Taing R; Chu J; Sreedhara A; Kannan A; Kei P; Shieh I; Graf T; Hu M
    Pharm Res; 2021 Mar; 38(3):531-548. PubMed ID: 33713012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Mechanistic Understanding of Monoclonal Antibody Interfacial Protection by Hydrolytically Degraded Polysorbate 20 and 80 under IV Bag Conditions.
    Kannan A; Giddings J; Mehta S; Lin T; Tomlinson A; Ritchie K; Shieh I; Saggu M; Doshi N
    Pharm Res; 2022 Mar; 39(3):563-575. PubMed ID: 35277841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Super Refined™ Polysorbate 20 With Respect to Polysorbate Degradation, Particle Formation and Protein Stability.
    Doshi N; Fish R; Padilla K; Yadav S
    J Pharm Sci; 2020 Oct; 109(10):2986-2995. PubMed ID: 32679214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stress-mediated polysorbate 20 degradation and its potential impact on therapeutic proteins.
    Aryal B; Lehtimaki M; Rao VA
    Pharm Res; 2024 Jun; 41(6):1217-1232. PubMed ID: 38740663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How enzymatic hydrolysis of polysorbate 20 influences colloidal protein stability.
    Glücklich N; Carle S; Diederichs T; Buske J; Mäder K; Garidel P
    Eur J Pharm Sci; 2023 Dec; 191():106597. PubMed ID: 37770006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of the specific causes of polysorbate 20 degradation in monoclonal antibody formulations containing multiple lipases.
    Zhang S; Riccardi C; Kamen D; Reilly J; Mattila J; Bak H; Xiao H; Li N
    Pharm Res; 2022 Jan; 39(1):75-87. PubMed ID: 34981317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Protein Particle Formation in IgG1 mAbs Formulated with PS20 Vs. PS80 When Subjected to Interfacial Dilatational Stress.
    Vaclaw C; Merritt K; Griffin VP; Whitaker N; Gokhale M; Volkin DB; Ogunyankin MO; Dhar P
    AAPS PharmSciTech; 2023 Apr; 24(5):104. PubMed ID: 37081185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fatty Acids Can Induce the Formation of Proteinaceous Particles in Monoclonal Antibody Formulations.
    Zhang J; He J; Smith KJ
    J Pharm Sci; 2022 Mar; 111(3):655-662. PubMed ID: 34666046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Free fatty acid particles in protein formulations, part 2: contribution of polysorbate raw material.
    Siska CC; Pierini CJ; Lau HR; Latypov RF; Fesinmeyer RM; Litowski JR
    J Pharm Sci; 2015 Feb; 104(2):447-56. PubMed ID: 25196966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding Particle Formation: Solubility of Free Fatty Acids as Polysorbate 20 Degradation Byproducts in Therapeutic Monoclonal Antibody Formulations.
    Doshi N; Demeule B; Yadav S
    Mol Pharm; 2015 Nov; 12(11):3792-804. PubMed ID: 26419285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polysorbate 20 Degradation in Biopharmaceutical Formulations: Quantification of Free Fatty Acids, Characterization of Particulates, and Insights into the Degradation Mechanism.
    Tomlinson A; Demeule B; Lin B; Yadav S
    Mol Pharm; 2015 Nov; 12(11):3805-15. PubMed ID: 26419339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. All-in-one stability indicating polysorbate 20 degradation root-cause analytics via UPLC-QDa.
    Carle S; Evers DH; Hagelskamp E; Garidel P; Buske J
    J Chromatogr B Analyt Technol Biomed Life Sci; 2024 Jan; 1232():123955. PubMed ID: 38128165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential Surface Adsorption Phenomena for Conventional and Novel Surfactants Correlates with Changes in Interfacial mAb Stabilization.
    Kanthe AD; Carnovale MR; Katz JS; Jordan S; Krause ME; Zheng S; Ilott A; Ying W; Bu W; Bera MK; Lin B; Maldarelli C; Tu RS
    Mol Pharm; 2022 Sep; 19(9):3100-3113. PubMed ID: 35882380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Linking aggregation and interfacial properties in monoclonal antibody-surfactant formulations.
    Kannan A; Shieh IC; Fuller GG
    J Colloid Interface Sci; 2019 Aug; 550():128-138. PubMed ID: 31055138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Competitive Surface Activity of Monoclonal Antibodies and Nonionic Surfactants at the Air-Water Interface Determined by Interfacial Rheology and Neutron Reflectometry.
    Tein YS; Zhang Z; Wagner NJ
    Langmuir; 2020 Jul; 36(27):7814-7823. PubMed ID: 32551695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.